SV2016005264A - Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas - Google Patents

Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas

Info

Publication number
SV2016005264A
SV2016005264A SV2016005264A SV2016005264A SV2016005264A SV 2016005264 A SV2016005264 A SV 2016005264A SV 2016005264 A SV2016005264 A SV 2016005264A SV 2016005264 A SV2016005264 A SV 2016005264A SV 2016005264 A SV2016005264 A SV 2016005264A
Authority
SV
El Salvador
Prior art keywords
tatk
compositions
formulations
cdkl5 fusion
fusion proteins
Prior art date
Application number
SV2016005264A
Other languages
English (en)
Spanish (es)
Inventor
Elisabetta Ciani
Franco Laccone
Original Assignee
Univ Bologna Alma Mater
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater filed Critical Univ Bologna Alma Mater
Publication of SV2016005264A publication Critical patent/SV2016005264A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737C-reactive protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022Cyclin-dependent kinase (2.7.11.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/405Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
SV2016005264A 2014-02-28 2016-08-26 Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas SV2016005264A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
SV2016005264A true SV2016005264A (es) 2017-02-15

Family

ID=53539745

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005264A SV2016005264A (es) 2014-02-28 2016-08-26 Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas

Country Status (33)

Country Link
US (4) US9290746B2 (enExample)
EP (2) EP3608334B1 (enExample)
JP (2) JP6629747B2 (enExample)
KR (1) KR102307276B1 (enExample)
CN (1) CN106255706A (enExample)
AU (2) AU2015221860B2 (enExample)
BR (1) BR112016019868B1 (enExample)
CA (1) CA2940401C (enExample)
CL (1) CL2016002142A1 (enExample)
CR (1) CR20160392A (enExample)
CY (2) CY1122644T1 (enExample)
DK (2) DK3608334T3 (enExample)
DO (1) DOP2016000220A (enExample)
EA (2) EA038000B1 (enExample)
ES (2) ES2885245T3 (enExample)
HR (2) HRP20191511T1 (enExample)
HU (2) HUE045393T2 (enExample)
IL (2) IL247481B (enExample)
LT (2) LT3608334T (enExample)
MX (2) MX2016011167A (enExample)
MY (1) MY181566A (enExample)
NI (1) NI201600127A (enExample)
PE (1) PE20161406A1 (enExample)
PH (1) PH12016501689B1 (enExample)
PL (2) PL3110837T3 (enExample)
PT (2) PT3110837T (enExample)
RS (2) RS59344B1 (enExample)
SG (2) SG10202000537RA (enExample)
SI (2) SI3110837T1 (enExample)
SM (2) SMT201900504T1 (enExample)
SV (1) SV2016005264A (enExample)
WO (1) WO2015128746A2 (enExample)
ZA (2) ZA201606655B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
US20200299654A1 (en) * 2017-11-30 2020-09-24 Amicus Therapeutics, Inc. Cdkl5 expression variants and cdkl5 fusion proteins
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
EP4073231A4 (en) * 2019-10-30 2024-06-05 Amicus Therapeutics, Inc. RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND METHODS OF PRODUCTION
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
IL303239A (en) 2020-12-01 2023-07-01 Univ Pennsylvania Compositions and their uses for the treatment of Engelmann syndrome
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632444A1 (en) * 2010-10-25 2013-09-04 Université d'Aix-Marseille TREATMENT OF MeCP2-ASSOCIATED DISORDERS
SMT201900504T1 (it) * 2014-02-28 2019-11-13 Univ Bologna Alma Mater Studiorum Proteine di fusione tatk-cdkl5, composizioni, formulazioni e loro uso

Also Published As

Publication number Publication date
MX2016011167A (es) 2017-04-06
SI3110837T1 (sl) 2019-12-31
EA202190727A3 (ru) 2021-11-30
IL247481A0 (en) 2016-11-30
SG10202000537RA (en) 2020-03-30
HRP20211324T1 (hr) 2021-11-26
JP2020062022A (ja) 2020-04-23
KR20170002372A (ko) 2017-01-06
IL247481B (en) 2020-07-30
JP6896050B2 (ja) 2021-06-30
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
EA201691691A1 (ru) 2017-05-31
JP6629747B2 (ja) 2020-01-15
DK3110837T3 (da) 2019-09-16
ZA201906304B (en) 2022-03-30
DK3608334T3 (da) 2021-08-23
EA202190727A2 (ru) 2021-07-30
EA038000B1 (ru) 2021-06-22
BR112016019868A2 (pt) 2017-10-17
EP3608334B1 (en) 2021-05-19
CL2016002142A1 (es) 2017-09-08
RS62244B1 (sr) 2021-09-30
KR102307276B1 (ko) 2021-09-30
WO2015128746A3 (en) 2015-11-26
LT3110837T (lt) 2019-10-10
CN106255706A (zh) 2016-12-21
PH12016501689A1 (en) 2016-10-03
NI201600127A (es) 2017-03-13
US20180327725A1 (en) 2018-11-15
DOP2016000220A (es) 2016-12-15
NZ723371A (en) 2023-11-24
AU2019219743A1 (en) 2019-09-19
ZA201606655B (en) 2020-05-27
HUE055282T2 (hu) 2021-11-29
EP3110837B1 (en) 2019-06-12
CY1124727T1 (el) 2022-07-22
PE20161406A1 (es) 2017-01-14
RS59344B1 (sr) 2019-10-31
SI3608334T1 (sl) 2021-11-30
AU2019219743B2 (en) 2020-10-29
CR20160392A (es) 2017-06-12
US9944910B2 (en) 2018-04-17
CA2940401C (en) 2022-11-29
AU2015221860A1 (en) 2016-09-08
US20150247134A1 (en) 2015-09-03
CA2940401A1 (en) 2015-09-03
BR112016019868B1 (pt) 2023-11-28
SMT202100478T1 (it) 2021-09-14
PT3608334T (pt) 2021-08-25
US20160194617A1 (en) 2016-07-07
SMT201900504T1 (it) 2019-11-13
AU2015221860B2 (en) 2019-09-12
EP3608334A1 (en) 2020-02-12
US20200199549A1 (en) 2020-06-25
EP3110837A2 (en) 2017-01-04
WO2015128746A2 (en) 2015-09-03
PL3110837T3 (pl) 2020-04-30
PH12016501689B1 (en) 2016-10-03
US9290746B2 (en) 2016-03-22
SG11201606863YA (en) 2016-09-29
PT3110837T (pt) 2019-09-12
HUE045393T2 (hu) 2019-12-30
PL3608334T3 (pl) 2021-11-22
HRP20191511T1 (hr) 2019-11-29
CY1122644T1 (el) 2021-03-12
IL275435B (en) 2021-07-29
MX2020001223A (es) 2022-05-31
ES2745335T3 (es) 2020-02-28
US10584318B2 (en) 2020-03-10
US10907138B2 (en) 2021-02-02
ES2885245T3 (es) 2021-12-13
IL275435A (en) 2020-08-31
JP2017507655A (ja) 2017-03-23
MX392778B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
SV2016005264A (es) Proteínas de fusión tatk-cdkl5, composiciones, formulaciones y uso de estas
CL2017001736A1 (es) Anticuerpos anti-cd47 y uso de los mismos.
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2019000259A1 (es) Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584)
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
MX369149B (es) Construcciones de anticuerpos para cdh19 y cd3.
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
BR112019012343A2 (pt) anticorpos il-11ra
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2016016886A (es) Anticuerpos anti-axl.
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
UY36678A (es) Anticuerpos anti-fcrn.
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
MX2016017025A (es) Formulaciones de proteinas.
MX2018000839A (es) Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos.
MA49249A (fr) Nouveaux anticorps anti-hsa
MX2018003445A (es) Expresion de proteinas que contienen fc.
EA201791437A1 (ru) Композиции микросфер c инкапсулированным в липиде газом и соответствующие способы
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas